The emergence of immune checkpoint inhibitors as effective cancer immunotherapy has effectively built a new “highway” connecting the promise of oncologic translational research to progress in treating advanced malignancies.
Matthew Zibelman, MD
Advertisement
Articles by Matthew Zibelman, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Data Readouts to Watch at the 2026 ASCO Annual Meeting
2
Alpha DaRT Elicits 100% Local Disease Control in Pancreatic Cancer
3
Navigating The Dynamic Landscape of Stem Cell Transplantation
4
FDA OKs Updated Guardant360 Liquid CDx with Expanded Molecular Profiling
5